Last $0.69 USD
Change Today -0.005 / -0.72%
Volume 9.0K
TTNP On Other Exchanges
Symbol
Exchange
OTC BB
Berlin
As of 11:19 AM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

titan pharmaceuticals inc (TTNP) Snapshot

Open
$0.69
Previous Close
$0.69
Day High
$0.69
Day Low
$0.68
52 Week High
10/8/13 - $1.27
52 Week Low
12/23/13 - $0.53
Market Cap
61.0M
Average Volume 10 Days
115.6K
EPS TTM
$-0.04
Shares Outstanding
89.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TITAN PHARMACEUTICALS INC (TTNP)

titan pharmaceuticals inc (TTNP) Related Businessweek News

No Related Businessweek News Found

titan pharmaceuticals inc (TTNP) Details

Titan Pharmaceuticals, Inc., a specialty pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. The company’s lead product candidate is Probuphine, a slow release implant formulation of buprenorphine in development for the long term maintenance treatment of opioid dependence. Its Probuphine is designed to maintain a stable and around the clock blood level of the medicine in patients for six months following a single treatment and utilizes ProNeura, a novel, proprietary, and long-term drug delivery technology. The company’s ProNeura is also used in developing products for the treatment of other chronic conditions, such as Parkinson’s disease. Its products also comprise Fanapt (iloperidone), an atypical antipsychotic for the treatment of schizophrenia. The company was founded in 1992 and is based in South San Francisco, California.

13 Employees
Last Reported Date: 03/31/14
Founded in 1992

titan pharmaceuticals inc (TTNP) Top Compensated Officers

Principal Executive Officer, President, Princ...
Total Annual Compensation: $300.0K
Executive Chairman and Member of Executive Co...
Total Annual Compensation: $210.0K
Compensation as of Fiscal Year 2013.

titan pharmaceuticals inc (TTNP) Key Developments

Titan Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Titan Pharmaceuticals Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net loss and comprehensive loss of $842,000 or $0.01 per diluted share on total revenue of $911,000 compared to net income and comprehensive income of $5,064,000 on total revenue of $2,198,000 reported a year ago. Loss from operations was $550,000 compared to $292,000 reported a year ago. For the six months, the company reported net loss and comprehensive loss of $2,646,000 or $0.03 per diluted share on total revenue of $1,823,000 compared to net income and comprehensive income of $11,065,000 or $0.10 per diluted share on total revenue of $7,372,000 reported a year ago. Loss from operations was $1,484,000 compared to $121,000 reported a year ago.

Titan Pharmaceuticals Inc. to Report Q2, 2014 Results on Aug 14, 2014

Titan Pharmaceuticals Inc. announced that they will report Q2, 2014 results at 11:00 AM, GMT Standard Time on Aug 14, 2014

Titan Pharmaceuticals Inc., Q2 2014 Earnings Call, Aug 14, 2014

Titan Pharmaceuticals Inc., Q2 2014 Earnings Call, Aug 14, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TTNP:US $0.69 USD -0.005

TTNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $43.84 USD -0.20
Reckitt Benckiser Group PLC 5,240 GBp -20.00
View Industry Companies
 

Industry Analysis

TTNP

Industry Average

Valuation TTNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.5x
Price/Book 17.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TITAN PHARMACEUTICALS INC, please visit www.titanpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.